A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma.

Trial Profile

A Phase 2a, Double-Blinded, Multi-Center, Escalating Dose Group, Placebo Controlled, Cross-Over Study to Evaluate the Safety, Efficacy and Tolerability of Subcutaneously Administered PL-3994 for the Treatment of Patients With Mild to Moderate Asthma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2014

At a glance

  • Drugs PL 3994 (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Palatin Technologies
  • Most Recent Events

    • 15 Dec 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 28 Feb 2014 Planned initiation date changed from 1 Jan 2014 to 1 Jun 2014 as reported by ClinicalTrials.gov.
    • 26 Aug 2013 Planned initiation date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top